Skye Bioscience, Inc. (SKYE)

NGM – Real vaqt narxi. Valyuta: USD

0.81

-0.07 (-7.56%)

Yopilishda: May 12, 2026, 4:00 PM EDT

0.80

-0.01 (-1.52%)

Bozor oldidan: May 13, 2026, 8:18 AM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Skye Bioscience, Inc. (SKYE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Skye Bioscience, Inc. (SKYE)

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Search stocks

Skye Bioscience, Inc. (SKYE)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Skye Bioscience, Inc. (SKYE)

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit

Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development

Skye Bioscience, Inc. (SKYE) Q4 2025 Earnings Call Transcript

Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Videolar

No Data

Press-relizlar

UPDATE – Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Skye Bioscience Reports First Quarter 2026 Financial Results and Business Update

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit